TC
TEVA icon

Taika Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Taika Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-35,000
Closed -$771K – 66
2024
Q4 		$771K Buy
+35,000
New +$637K 0.59% 36

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Taika Capital's TEVA Position: Q1 2025 in Review

Taika Capital sold out of Teva Pharmaceuticals (TEVA) in Q1 2025, closing a stake of 35,000 shares — an estimated $771K sold.

Taika Capital first reported a position in TEVA in Q4 2024 and held it in 1 quarter. The position peaked at $771K in Q4 2024. 561 funds tracked by Wall St. Rank hold TEVA as of Q1 2025.

  • Taika Capital reported no remaining Teva Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Taika Capital sold 35,000 Teva Pharmaceuticals shares in Q1 2025, an estimated $771K.
  • Taika Capital first reported a position in Teva Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Taika Capital's Teva Pharmaceuticals position peaked at $771K in Q4 2024.
  • 561 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2025.

Based on Taika Capital's 13F filing for Q1 2025.